The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Sen. Bill Cassidy, a Republican from Louisiana, said he was swayed after nominee Robert F. Kennedy Jr. agreed to significant vaccine concessions, Stat and The Hill reported. Also in the news, Pfizer's ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...

The tech giant's fast-growing cloud-computing business decelerated last quarter. Some analysts said tougher comparisons, harsher weather and holiday timing may have put pressure on the fast-casual ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Pfizer CEO Albert Bourla unpacks the impact of the nomination on 'The Claman Countdown.' If you cross paths with these ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...